ibrutinib + prednisone

**Ibrutinib + prednisone** is a combination therapy used for the treatment of moderate or severe chronic graft-versus-host disease (cGVHD), particularly in patients post-allogeneic stem cell transplantation who require systemic corticosteroid therapy and have not received prior systemic treatment for cGVHD[1][2][3]. - **Ibrutinib** is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK), an enzyme critical for B-cell receptor signaling, leading to reduced B-cell survival, proliferation, and activation. It also inhibits IL-2-inducible T-cell kinase (ITK), affecting T-cell function, and is classified as a targeted therapy[1][3]. - **Prednisone** is a synthetic glucocorticoid corticosteroid that suppresses immune response and inflammation through the glucocorticoid receptor, leading to broad immunosuppressive and anti-inflammatory effects[1][3]. This combination was evaluated in the phase III iNTEGRATE trial, which found no statistically significant benefit for the addition of ibrutinib to prednisone for frontline cGVHD compared to prednisone alone, though safety and event-free survival profiles were characterized[1][2][3].